|
| 37399238 | Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? | Hepatology | 2024 |
| 37904314 | Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. | Aliment Pharmacol Ther | 2024 |
| 37945164 | Primary Biliary Cholangitis: Pathophysiology. | Clin Liver Dis | 2024 |
| 36343847 | GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus. | Clin Gastroenterol Hepatol | 2023 |
| 37534935 | Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis. | Hepatol Commun | 2023 |
| 37191344 | Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis. | Gut Microbes | 2023 |
| 37157905 | Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival. | Liver Int | 2023 |
| 37386786 | Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. | Hepatology | 2023 |
| 37184523 | Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study. | Hepatol Commun | 2023 |
| 36964518 | Improving quality of life in patients with rare autoimmune liver diseases by structured peer-delivered support (Q.RARE.LI): study protocol for a transnational effectiveness-implementation hybrid trial. | BMC Psychiatry | 2023 |
| 37026715 | Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells. | Hepatol Commun | 2023 |
| 36621963 | Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis. | Am J Gastroenterol | 2023 |
| 36809835 | New Treatment Paradigms in Primary Biliary Cholangitis. | Clin Gastroenterol Hepatol | 2023 |
| 36468575 | Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe. | Eur J Gastroenterol Hepatol | 2023 |
| 36870613 | Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem? | J Hepatol | 2023 |
| 36639314 | Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581]. | J Hepatol | 2023 |
| 35961518 | UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. | Clin Gastroenterol Hepatol | 2023 |
| 34231037 | Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. | Eur Radiol | 2022 |
| 35609437 | The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study. | EBioMedicine | 2022 |
| 35397207 | Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. | Am J Hum Genet | 2022 |
| 35367282 | A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. | J Hepatol | 2022 |
| 35777587 | Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. | J Hepatol | 2022 |
| 36150526 | Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. | Gastroenterology | 2022 |
| 36138566 | Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid. | Aliment Pharmacol Ther | 2022 |
| 36270719 | Autoantibodies in Primary Biliary Cholangitis. | Clin Liver Dis | 2022 |
| 36267872 | Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis. | JHEP Rep | 2022 |
| 36327436 | A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis. | Am J Gastroenterol | 2022 |
| 36223935 | Trends in liver transplantation for autoimmune liver diseases: a Canadian study. | Can J Surg | 2022 |
| 35977610 | Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!" | J Hepatol | 2022 |
| 34951722 | Machine learning in primary biliary cholangitis: A novel approach for risk stratification. | Liver Int | 2022 |
| 35220609 | Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. | Hepatology | 2022 |
| 35143897 | Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. | J Hepatol | 2022 |
| 35133427 | Elevated Serum Aminotransferases. | JAMA | 2022 |
| 34403559 | Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. | Liver Int | 2022 |
| 34548339 | The human liver microenvironment shapes the homing and function of CD4<sup>+</sup> T-cell populations. | Gut | 2022 |
| 34626833 | Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. | Clin Gastroenterol Hepatol | 2022 |
| 32562892 | Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom. | Clin Gastroenterol Hepatol | 2021 |
| 35989897 | Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. | Can Liver J | 2021 |
| 33493696 | The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude. | Clin Gastroenterol Hepatol | 2021 |
| 33488578 | CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis. | Front Immunol | 2021 |
| 33484775 | A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. | J Hepatol | 2021 |
| 33872692 | Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. | J Hepatol | 2021 |
| 33898959 | Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. | JHEP Rep | 2021 |
| 33584535 | Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. | Front Endocrinol (Lausanne) | 2021 |
| 34406347 | Sex Disparity in Liver Transplant and Access to Living Donation. | JAMA Surg | 2021 |
| 34425003 | Editorial: liver disease in secondary care-'money or your life'. Authors' reply. | Aliment Pharmacol Ther | 2021 |
| 33942335 | Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males? | Hepatology | 2021 |
| 33941746 | A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. | Am J Gastroenterol | 2021 |
| 34129689 | The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis. | Hepatology | 2021 |
| 34181776 | Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. | Aliment Pharmacol Ther | 2021 |